Wenzhou Kangning Hospital Management
Management criteria checks 4/4
Wenzhou Kangning Hospital's CEO is Lianyue Wang, appointed in Sep 2011, has a tenure of 13.25 years. total yearly compensation is CN¥658.80K, comprised of 71.1% salary and 28.9% bonuses, including company stock and options. directly owns 4.74% of the company’s shares, worth HK$42.43M. The average tenure of the management team and the board of directors is 2.9 years and 3.3 years respectively.
Key information
Lianyue Wang
Chief executive officer
CN¥658.8k
Total compensation
| CEO salary percentage | 71.1% |
| CEO tenure | 13.3yrs |
| CEO ownership | 4.7% |
| Management average tenure | 2.9yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Wenzhou Kangning Hospital Co., Ltd.'s (HKG:2120) Share Price Matching Investor Opinion
Sep 26
We Think The Compensation For Wenzhou Kangning Hospital Co., Ltd.'s (HKG:2120) CEO Looks About Right
May 23Estimating The Fair Value Of Wenzhou Kangning Hospital Co., Ltd. (HKG:2120)
Feb 28Investors Continue Waiting On Sidelines For Wenzhou Kangning Hospital Co., Ltd. (HKG:2120)
Jan 19Wenzhou Kangning Hospital (HKG:2120) Has A Somewhat Strained Balance Sheet
Nov 23Wenzhou Kangning Hospital (HKG:2120) Could Be Struggling To Allocate Capital
Jun 16Returns Are Gaining Momentum At Wenzhou Kangning Hospital (HKG:2120)
Mar 23Is Wenzhou Kangning Hospital (HKG:2120) Using Too Much Debt?
Dec 06Returns On Capital Are Showing Encouraging Signs At Wenzhou Kangning Hospital (HKG:2120)
Aug 11Calculating The Fair Value Of Wenzhou Kangning Hospital Co., Ltd. (HKG:2120)
Jul 09Wenzhou Kangning Hospital (HKG:2120) Is Experiencing Growth In Returns On Capital
May 12Wenzhou Kangning Hospital (HKG:2120) Has A Pretty Healthy Balance Sheet
Apr 10Wenzhou Kangning Hospital Co., Ltd.'s (HKG:2120) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Feb 25Will Wenzhou Kangning Hospital (HKG:2120) Multiply In Value Going Forward?
Jan 17
Should You Use Wenzhou Kangning Hospital's (HKG:2120) Statutory Earnings To Analyse It?
Dec 23If You Had Bought Wenzhou Kangning Hospital's (HKG:2120) Shares Five Years Ago You Would Be Down 42%
Dec 10Can Mixed Fundamentals Have A Negative Impact on Wenzhou Kangning Hospital Co., Ltd. (HKG:2120) Current Share Price Momentum?
Nov 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥93m |
| Mar 31 2024 | n/a | n/a | CN¥89m |
| Dec 31 2023 | CN¥659k | CN¥469k | CN¥86m |
| Sep 30 2023 | n/a | n/a | CN¥33m |
| Jun 30 2023 | n/a | n/a | -CN¥19m |
| Mar 31 2023 | n/a | n/a | -CN¥22m |
| Dec 31 2022 | CN¥683k | CN¥516k | -CN¥24m |
| Sep 30 2022 | n/a | n/a | CN¥12m |
| Jun 30 2022 | n/a | n/a | CN¥48m |
| Mar 31 2022 | n/a | n/a | CN¥46m |
| Dec 31 2021 | CN¥489k | CN¥397k | CN¥44m |
| Sep 30 2021 | n/a | n/a | CN¥45m |
| Jun 30 2021 | n/a | n/a | CN¥54m |
| Mar 31 2021 | n/a | n/a | CN¥55m |
| Dec 31 2020 | CN¥483k | CN¥326k | CN¥56m |
| Sep 30 2020 | n/a | n/a | CN¥49m |
| Jun 30 2020 | n/a | n/a | CN¥42m |
| Mar 31 2020 | n/a | n/a | CN¥49m |
| Dec 31 2019 | CN¥438k | CN¥325k | CN¥57m |
| Sep 30 2019 | n/a | n/a | CN¥74m |
| Jun 30 2019 | n/a | n/a | CN¥91m |
| Mar 31 2019 | n/a | n/a | CN¥86m |
| Dec 31 2018 | CN¥455k | CN¥324k | CN¥81m |
| Sep 30 2018 | n/a | n/a | CN¥73m |
| Jun 30 2018 | n/a | n/a | CN¥65m |
| Mar 31 2018 | n/a | n/a | CN¥57m |
| Dec 31 2017 | CN¥449k | CN¥324k | CN¥49m |
Compensation vs Market: Lianyue's total compensation ($USD90.27K) is below average for companies of similar size in the Hong Kong market ($USD230.88K).
Compensation vs Earnings: Lianyue's compensation has been consistent with company performance over the past year.
CEO
Lianyue Wang (55 yo)
13.3yrs
Tenure
CN¥658,800
Compensation
Ms. Lianyue Wang serves as General Manager at Wenzhou Kangning Hospital Co., Ltd. Since September 2011 and has been its Executive Director since April 2013 were she is primarily responsible for the overall...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 10.3yrs | CN¥580.73k | 25.64% HK$ 229.4m | |
| GM & Executive Director | 13.3yrs | CN¥658.80k | 4.74% HK$ 42.4m | |
| Vice GM | 10.4yrs | CN¥884.56k | 0.21% HK$ 1.9m | |
| Chief Financial Officer | 2.9yrs | no data | no data | |
| Chairman of Supervisory Committee | 2.5yrs | no data | no data | |
| Joint Company Secretary | 2.4yrs | no data | no data |
2.9yrs
Average Tenure
53yo
Average Age
Experienced Management: 2120's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 10.3yrs | CN¥580.73k | 25.64% HK$ 229.4m | |
| GM & Executive Director | 11.7yrs | CN¥658.80k | 4.74% HK$ 42.4m | |
| Vice GM | 1.5yrs | CN¥884.56k | 0.21% HK$ 1.9m | |
| Chairman of Supervisory Committee | 2.8yrs | no data | no data | |
| Employee Representative Supervisor | 10.3yrs | CN¥38.00k | no data | |
| Non-Executive Director | 3.2yrs | no data | no data | |
| Independent Supervisor | 7.5yrs | no data | no data | |
| Shareholder Representative Supervisor | 3.2yrs | no data | no data | |
| Independent Non Executive Director | 4.5yrs | CN¥70.00k | no data | |
| Non-Executive Director | 3.5yrs | no data | no data | |
| Independent Non Executive Director | 1.5yrs | CN¥35.00k | no data | |
| Independent Non-Executive Director | 1.5yrs | CN¥35.00k | no data |
3.3yrs
Average Tenure
48.5yo
Average Age
Experienced Board: 2120's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 21:27 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Wenzhou Kangning Hospital Co., Ltd. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ruili Bian | Citigroup Inc |
| Ying Shao | CLSA |
| Sze Chuen Tam | Core Pacific -Yamaichi International (H.K.) Limited |